🇺🇸 FDA
Pipeline program

Chemotherapy+PD-1 inhibitor+8Gy x 3f

20241777

Phase 2 small_molecule active

Quick answer

Chemotherapy+PD-1 inhibitor+8Gy x 3f for HR+HER2- Breast Cancer is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
HR+HER2- Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials